Multiple Myeloma

Ursula Linne-Mclaren, RN, reviews a clinical scenario in a relapsed/ refractory multiple myeloma patient.

Findings from the phase 3 PERSEUS trial support the supplemental New Drug Application for the daratumumab and hyaluronidase-fihj combination in transplant-eligible newly diagnosed multiple myeloma.

Patients with multiple myeloma appear to feel confident in being able to report adverse effects associated with bortezomib independently via digital tools.

A positive CHMP opinion may lead to an approval of idecabtagene vicleucel in the European Union for patients with relapsed/refractory multiple myeloma.

Adding daratumumab to VRd induction and consolidation therapy plus lenalidomide maintenance provides a benefit with respect to MRD-negative status among patients with multiple myeloma.

Present initial results from the Phase 1 RedirecTT-1 trial exploring the combination of teclistamab and talquetamab in relapsed/refractory multiple myeloma.

Compare outcomes between ide-cel chimeric antigen receptor T-cell (CAR-T) therapy and standard treatment regimens such as pomalidomide and daratumumab combinations in patients with heavily pretreated relapsed and refractory multiple myeloma.

Oncology Clinical Pharmacist Specialist Amir Ali delves into potential challenges related to access and the use of this therapy, providing a comprehensive perspective on the complexities of incorporating GPRC5-targeting bispecifics into R/R MM patient management.

Amir discusses challenges encountered during the administration process, offering valuable perspectives on the practical considerations and complexities in delivering these innovative therapies.

Amir Ali, PharmD reviews a clinical scenario in a relapsed/ refractory multiple myeloma patient.

Present real-world data on the efficacy and safety of the ixazomib-lenalidomide-dexamethasone combination in patients with relapsed/refractory multiple myeloma outside of clinical trials.

Examine outcomes such as overall survival, progression-free survival, and response rates in multiple myeloma patients who have experienced biochemical or clinical progression after prior lines of therapy.

Experts dive into the complexities of defining and treating high-risk Multiple Myeloma (MM) and discuss the role of ASCT in newly diagnosed MM and weigh the considerations for recommending transplants, including insights on the selection criteria for tandem transplantations.

Philippe Moreau, MD, discusses recent data from the IFM 2018 trial which evaluated Dara-KRd induction and consolidation plus double transplants in high risk, TE NDMM.

An expert briefly reviews the role of GPRC5C-targeting bispecifics in Relapsed/Refractory Multiple Myeloma (R/R MM) following four previous lines of therapy, comparing its efficacy and characteristics with other treatment options like BCMA and CAR-T therapies. She also provides insights into the benefits, risks, and potential challenges related to the access and utilization of GPRC5D-targeting bispecifics, providing a comprehensive overview of considerations in the advanced R/R MM treatment landscape.

Dr. Costello explores the mechanism of action (MOA) of talquetamab and its distinctive role in Relapsed/Refractory Multiple Myeloma (R/R MM), drawing comparisons with other bispecific therapies.

A group of experts discussed the approval process for teclistamab use in patients with multiple myeloma.

A summary of key discussion points and an overview of the evidence presented to inform the dialogue.

Sagar Lonial, MD, and Ellen Marin, PA-C, discuss the impact and key takeaways from their study as well as study limitations and future directions.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to share their closing thoughts before the 2-Minute Drill winner is announced.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to provide shameless plugs from this year's conference.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss the biggest winner from the 2023 meeting.

Three medical oncologists explore the influence of MRD negativity rates on treatment decisions and discover the ideal patient profile for quadruplet regimen.

Larry Anderson, MD, goes over the recent data from the IsKia trial which investigated IsaKRd in pre-transplant induction and post-transplant consolidation in TE NDMM.

Three physicians explore the criteria for determining an adequate or successful response during the induction phase in patients with TE NDMM and uncover the intricate considerations shaping the choice of maintenance regimens.

Ellen Marin, PA-C, presents the study conclusions and discusses its implications on managing CRS associated with teclistamab with Dr. Lonial.

Study results show that prophylactic tocilizumab reduces CRS incidence and severity in patients receiving teclistamab.

A population of patients with multiple myeloma describes experiencing challenges including confusion regarding the complexities of their diagnoses and managing chronic treatment-related adverse effects in a qualitative study.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss data from the conference that require the most follow-up.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss data from the conference that are most likely to lead to an FDA approval.